Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 15:10:2020-9-1.
doi: 10.7573/dic.2020-9-1. eCollection 2021.

Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases

Valeria Nucera  1 , Elisabetta Gerratana  1 , Manuela Giallanza  1 , Laura La Corte  1 , Donatella Sangari  1 , Fabiola Atzeni  1
Affiliations
Review

Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases

Valeria Nucera et al. Drugs Context. .

Abstract

Interstitial lung diseases (ILDs) are some of the first and most serious complications of connective tissue diseases (CTDs). However, the pathogenesis of CTD-related ILDs (CTD-ILDs) is still unclear and their treatment often depends on functional and radiographic disease progression as well as on patient age and comorbidities. It can be difficult to manage CTD-ILDs due to their heterogeneous nature, the lack of robust therapeutic data, and the few well-defined outcome measures. This review focuses on cyclophosphamide due to its crucial role in the treatment of systemic sclerosis-related ILD, particularly in the case of patients with progressive ILD. This narrative review was performed using PubMed, Medline, and Cochrane Library databases to retrieve English language papers published between 2000 and April 2020 concerning the treatment of CTD-ILDs with cyclophosphamide.

Keywords: comorbidities; connective tissue diseases; cyclophosphamide; disease-modifying antirheumatic drugs; interstitial lung diseases.

PubMed Disclaimer

Conflict of interest statement

Disclosure and potential conflicts of interest: The authors declare that they have no potential conflicts of interest with respect to the research, authorship, or publication of this article. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/11/dic.2020-9-1-COI.pdf

References

    1. Atzeni F, Gerardi MC, Barilaro G, et al. Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. Expert Rev Clin Immunol. 2018;14(1):69–82. doi: 10.1080/1744666X.2018.1411190. - DOI - PubMed
    1. Hsu E, Shi H, Jordan RM, et al. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum. 2011;63(3):783–794. doi: 10.1002/art.30159. - DOI - PMC - PubMed
    1. Peljto AL, Steele MP, Fingerlin TE, et al. The pulmonary fibrosis associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. Chest. 2012;142(6):1584–1588. doi: 10.1378/chest.12-0110. - DOI - PMC - PubMed
    1. Hant FN, Ludwicka-Bradley A, Wang HJ, et al. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol. 2009;36(4):773–780. doi: 10.3899/jrheum.080633. - DOI - PubMed
    1. de Carvalho EF, Parra ER, de Souza R, et al. Arterial and interstitial remodelling processes in non-specific interstitial pneumonia: systemic sclerosis versus idiopathic. Histopathology. 2008;53(2):195–204. doi: 10.1111/j.1365-2559.2008.03072.x. - DOI - PubMed

LinkOut - more resources